ADCT — ADC Therapeutics SA
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1771910 ·
Last close
$1.35
Market Cap
$189.89M
52W High
$4.98
52W Low
$0.78
ADV30
1,593,130
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 21,716,000 | 19,736,000 | -14,412,000 | -25,304,000 | 255,863,000 | 189,204,000 | 505,036,000 |
| Jun 2026 | 19,248,000 | 16,899,000 | -22,778,000 | -16,565,000 | 279,379,000 | 219,107,000 | 507,584,000 |
| Mar 2026 | 20,851,000 | 17,236,000 | -25,245,000 | -32,968,000 | 291,496,000 | 231,008,000 | 507,873,000 |
| Dec 2025 | 23,058,000 | 21,359,000 | -18,123,000 | -6,409,000 | 323,150,000 | 261,338,000 | 508,984,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-100,518,000
Investing CF
$627,000
Financing CF
$54,302,000
CapEx
$-296,000
Dividends Paid
—
Buybacks
$-837,000
EPS Diluted TTM
$-0.52
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,710,778,000
Inventory
$5,626,000
Receivables
$28,417,000
ST Investments
—
EBIT TTM
$-29,046,000
Pretax Income TTM
$-81,650,000
Interest Exp TTM
$52,604,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$84,873,000
EBITDA
$-78,351,248
Free Cash Flow
$-74,586,496
Enterprise Value
$441,191,904
Total Cash
$189,204,000
Total Debt
$441,908,992
Shares Out
140,661,880
Trailing EPS
$-0.46
Book Value
$-1.95
ROE
—
ROA
-18.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 81,357,000 | -107,207,000 | -142,623,000 | 323,150,000 | 508,984,000 | -185,834,000 | -141,174,000 |
| Dec 2024 | 70,837,000 | -129,591,000 | -157,846,000 | 321,980,000 | 524,622,000 | -202,642,000 | -123,835,000 |
| Dec 2023 | 69,558,000 | -165,051,000 | -240,053,000 | 354,782,000 | 503,031,000 | -148,249,000 | -118,686,000 |
| Dec 2022 | 209,908,000 | -122,987,000 | -157,128,000 | 490,859,000 | 411,408,000 | 79,451,000 | -138,311,000 |
TTM Snapshot
Revenues TTM
$79,584,000
NetIncome TTM
$-96,908,000
OpCashFlow TTM
—
Assets (Latest)
$279,379,000
Forward EPS
$-1.49
Max Pain — expiry 2027-01-15
max pain strike: $2.50 · spot: $1.37 · call oi: 1,812 · put oi: 0
Expected Move to 2027-01-15:
±$1.60
(116.79%) —
implied range
$-0.23 –
$2.97
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RNAC | Cartesian Therapeutics, Inc. | $186.68M | $6.12 | — |
| TRDA | Entrada Therapeutics, Inc. | $194.19M | $4.96 | — |
| SIGA | SIGA TECHNOLOGIES INC | $196.16M | $2.73 | — |
| WHWK | Whitehawk Therapeutics, Inc. | $181.75M | $3.08 | — |
| VOGX | Vogenx, Inc. | $200.25M | $13.48 | — |
News headlines (Yahoo Finance, 1h cache)
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates
2026-11-09 12:40 · Yahoo
ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates
2026-11-09 12:30 · Yahoo
ADC Therapeutics Reports Strong Lymphoma Responses, Plans Phase III Study
2026-11-04 23:14 · Yahoo
ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program
2026-11-04 14:00 · Yahoo
ADC Therapeutics to Present at November Investor Conferences
2026-11-03 12:15 · Yahoo
ADC Therapeutics Announces New Employee Inducement Grant
2026-11-02 21:05 · Yahoo
ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026
2026-11-02 12:15 · Yahoo
ADC Therapeutics Announces ZYNLONTA® Updates in Japan
2026-10-29 11:30 · Yahoo
ADC Therapeutics Cuts Debt, Extends Runway Ahead of Key Drug Data, RBC Says
2026-10-09 15:27 · Yahoo
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
2026-10-08 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.